Low direct Parkinson's therapeutic discovery value because it lacks mechanistic, biomarker, or intervention detail, but it flags a non-pharmacological neurorehabilitation concept that could inform quality-of-life and symptomatic care studies.

These objective, remote digital biomarkers could increase sensitivity and temporal resolution in PD trials and monitoring, enabling smaller/shorter studies and earlier detection of treatment effects to accelerate therapeutic development.

Provides a simple, noninvasive, high-accuracy candidate biomarker for detecting subtle early postural impairment that could aid earlier diagnosis, trial enrollment, and objective outcome measurement, though it does not advance mechanistic or therapeutic targets.

Enhancing participant engagement and study procedures improves enrollment, diversity, and quality/quantity of biospecimens and clinical data, which indirectly accelerates biomarker discovery and translational Parkinson's therapeutic research despite lacking direct mechanistic or intervention…

LRRK2 is a major Parkinson's disease-linked protein, so peptides that disrupt its interaction with PP2A are useful mechanistic tools with potential therapeutic relevance, but the work lacks cellular, functional, or in vivo validation needed for strong translational impact.

Although it does not identify molecular therapeutic targets, the work provides a robust, multidomain biomarker for fall-risk stratification and patient selection/outcome measurement in trials aimed at reducing falls or treating balance and autonomic symptoms in PD.

Although not mechanistic or therapeutic itself, the study provides a validated, ancestrally diverse genetic resource that improves variant ascertainment for target validation, cohort selection, and equitable discovery efforts that can enable future therapy development.

As a low-cost, noninvasive imaging biomarker with reported high accuracy and interrater reliability, TCBS can support diagnosis, differential diagnosis, and patient stratification in clinical research and trials, though it provides little direct mechanistic or therapeutic insight.

These well-characterized, autopsy-matched iPSC lines provide a valuable resource to create neural derivatives that can be directly compared to corresponding brain tissue, enabling more physiologically relevant PD modeling and downstream therapeutic or biomarker studies even though the paper does…

Offers a mechanistic, translatable framework that can inform DBS parameter optimization and generate hypotheses about network-level dysfunction in PD, but has limited direct applicability to molecular targets or conventional drug discovery.

Although not mechanistic or therapeutic, the study informs prognosis and patient stratification for clinical trials by identifying older age at PD onset as a key predictor of dementia risk in community settings.

This identifies an actionable microbiome→CA9→ferroptosis pathway that could be targeted via microbiome modulation, CA9 modulation, or ferroptosis inhibitors and provides biomarker/repurposing opportunities, though the missing abstract reduces confidence in details.

A demonstrated link would point to iron accumulation as a potential imaging biomarker and mechanistic target (e.g., chelation, antioxidant strategies) for non-motor psychiatric symptoms in PD, but the missing abstract and review-only format limit immediate therapeutic actionability.

Highlights sphingolipid metabolism as a potential link between vascular insufficiency and PD-related cognitive decline—an actionable metabolic pathway—but the correction notice and missing abstract limit immediate translational or therapeutic insights.

It points to potentially targetable mechanisms (microbiome modulation and BBB-protective strategies) and biomarker opportunities relevant to PD therapeutics, though lack of abstract/details limits immediate actionability.

Highlights clinically important, measurable symptomatic burdens that can guide outcome selection and symptomatic intervention priorities in trials, but offers little mechanistic or drug-discovery information.

It helps clinicians and patients identify trustworthy exercise resources for symptom management, but offers minimal direct value for Parkinson's drug discovery or translational research.

Limited direct value for molecular therapeutic discovery but informs development of tailored behavioral interventions and symptom-management strategies to improve quality of life in PD.

This paper has minimal direct relevance to Parkinson's therapeutic discovery because it addresses cardiac electrophysiology and structural cardiomyopathy rather than neurodegenerative mechanisms (e.g., alpha-synuclein, mitochondria, inflammation) or actionable PD targets.

Offers a human-relevant platform to study microglia-driven inflammation and genetics relevant to Parkinson's disease and to prioritize targets and screens for therapeutic development, though as a review it provides synthesis rather than new actionable experimental findings.